Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.

doi:10.1158/1078-0432.CCR-17-3438

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2018

Li Shuai, Liu Shengwu, Deng Jiehui, Akbay Esra A, Hai Josephine, Ambrogio Chiara, Zhang Long, Zhou Fangyu, Jenkins Russell W, Adeegbe Dennis O, Gao Peng, Wang Xiaoen, Paweletz Cloud P, Herter-Sprie Grit S, Chen Ting, Gutiérrez-Quiceno Laura, Zhang Yanxi, Merlino Ashley A, Quinn Max M, Zeng Yu, Yu Xiaoting, Liu Yuting, Fan Lichao, Aguirre Andrew J, Barbie David A, Yi Xianghua, Wong Kwok-Kin

Abstract excerpt

Purpose: Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some agents are under development against downstream signaling pathways, such as MEK inhibitors. However, it remains controversial whether MEK inhibitors can boost current chemotherapy in KRAS-mutant lung tumors in clinic. Considering the genomic heterogeneity among patients with lung cancer, it is valuable to test...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Benzimidazoles

Share to MAP Kinase Kinase Kinase 1

Share to MAP Kinase Signaling System

Share to NIH 3T3 Cells

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 29945997
DOI: 10.1158/1078-0432.CCR-17-3438
PMCID: PMC6482448

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.PMID 29945997Read ↗

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.Semantic proximity Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.Semantic proximity Read ↗

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.Semantic proximity Read ↗

Targeting the MAPK Pathway in KRAS-Driven Tumors.Semantic proximity Read ↗

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Semantic proximity Read ↗

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.Semantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read ↗

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read ↗

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.Semantic proximity Read ↗

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.